Journal of Clinical Oncology, Vol 10, 447-451, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Competing events determining relapse-free survival in limited small- cell lung carcinoma. The French Cancer Centers' Lung Group

R Arriagada, A Kramar, T Le Chevalier and H De Cremoux
Institut Gustave-Roussy, Villejuif, France.

PURPOSE: We report results in terms of relapse-free survival (RFS), obtained in patients with limited small-cell lung carcinoma (SCLC) treated by four consecutive alternating protocols, using a competing risk approach with local recurrences, distant metastases, and death unrelated to cancer as competing events. PATIENTS AND METHODS: Two hundred two patients with limited SCLC were included in four consecutive protocols alternating radiotherapy and chemotherapy (CT). The alternating schedule consisted of six cycles of CT (doxorubicin, etoposide [VP16213], and cyclophosphamide [CAVP16], plus methotrexate in the first protocol; cisplatin replaced methotrexate in the other three protocols) and three courses of thoracic radiotherapy at a total dose of 45, 55, 65, and 61 Gy in the four consecutive protocols, respectively (accelerated hyperfractionation was used in the first course of the fourth protocol). A 1-week rest followed each CT cycle and each course of radiotherapy. Seventy-six percent of patients were in complete remission at the end of the induction treatment. RFS variables were determined according to a model assuming competing risks to define the first cause of failure (local disease, distant metastasis, or intercurrent death). RESULTS: No significant differences were observed between the four treatment groups. Overall results showed a 2-year cumulative incidence rate of failure of 75%. When analyzed, the first cause of failure was local recurrence only, 33%; distant only, 25%; distant and local simultaneously, 9%; and intercurrent death, 8%. CONCLUSIONS: The methodology of competing risks allowed an unequivocal description of first events in limited SCLC. The extent of the local problem has been relatively overshadowed by the use of conventional descriptive methods.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-Y. Han, K. H. Cho, D. H. Lee, H. Y. Kim, E.-A Kim, S. Y. Lee, and J. S. Lee Phase II Study of Irinotecan Plus Cisplatin Induction Followed by Concurrent Twice-Daily Thoracic Irradiation With Etoposide Plus Cisplatin Chemotherapy for Limited-Disease Small-Cell Lung Cancer J. Clin. Oncol., May 20, 2005; 23(15): 3488 - 3494. [Abstract] [Full Text] [PDF]

				B. Brenner, L. H. Tang, D. S. Klimstra, and D. P. Kelsen Small-Cell Carcinomas of the Gastrointestinal Tract: A Review J. Clin. Oncol., July 1, 2004; 22(13): 2730 - 2739. [Abstract] [Full Text] [PDF]

				R. Arriagada, T. Le Chevalier, A. Riviere, P. Chomy, I. Monnet, E. Bardet, J. A Santos-Miranda, C. Le Pechoux, M. Tarayre, S. Benhamou, et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients Ann. Onc., May 1, 2002; 13(5): 748 - 754. [Abstract] [Full Text] [PDF]

				J.-L. Pujol, J.-P. Daures, A. Riviere, E. Quoix, V. Westeel, X. Quantin, J.-L. Breton, E. Lemarie, M. Poudenx, B. Milleron, et al. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study J Natl Cancer Inst, February 21, 2001; 93(4): 300 - 308. [Abstract] [Full Text] [PDF]

				A. Elias Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 531S - 538S. [Abstract] [Full Text] [PDF]

				A. Auperin, R. Arriagada, J.-P. Pignon, C. Le Pechoux, A. Gregor, R. J. Stephens, P. E.G. Kristjansen, B. E. Johnson, H. Ueoka, H. Wagner, et al. Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission N. Engl. J. Med., August 12, 1999; 341(7): 476 - 484. [Abstract] [Full Text] [PDF]

				A. Elias, J. Ibrahim, A. T. Skarin, C. Wheeler, M. McCauley, L. Ayash, P. Richardson, L. Schnipper, K. H. Antman, and E. Frei III Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome J. Clin. Oncol., April 1, 1999; 17(4): 1175 - 1175. [Abstract] [Full Text] [PDF]

				R. Arriagada, T. Le Chevalier, J.-P. Pignon, A. Riviere, I. Monnet, P. Chomy, C. Tuchais, M. Tarayre, and P. Ruffie Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung Cancer N. Engl. J. Med., December 16, 1993; 329(25): 1848 - 1852. [Abstract] [Full Text]